382 related articles for article (PubMed ID: 26969216)
21. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
[TBL] [Abstract][Full Text] [Related]
22. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results.
Bolzicco G; Favretto MS; Scremin E; Tambone C; Tasca A; Guglielmi R
Technol Cancer Res Treat; 2010 Oct; 9(5):473-7. PubMed ID: 20815418
[TBL] [Abstract][Full Text] [Related]
23. SHARP hypofractionated stereotactic radiotherapy for localized prostate cancer: a biochemical response to treatment.
Rucinska M; Osowiecka K; Kieszkowska Grudny A; Nawrocki S
J BUON; 2019; 24(5):2099-2106. PubMed ID: 31786881
[TBL] [Abstract][Full Text] [Related]
24. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
[TBL] [Abstract][Full Text] [Related]
25. Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation.
Geara FB; Bulbul M; Khauli RB; Andraos TY; Abboud M; Al Mousa A; Sarhan N; Salem A; Ghatasheh H; Alnsour A; Ayoub Z; Gheida IA; Charafeddine M; Shahait M; Shamseddine A; Gheida RA; Khader J
Radiat Oncol; 2017 Sep; 12(1):149. PubMed ID: 28882187
[TBL] [Abstract][Full Text] [Related]
26. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial.
Pasquier D; Peiffert D; Nickers P; Maingon P; Pommier P; Lacornerie T; Martinage G; Tresch E; Lartigau E
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):116-123. PubMed ID: 31604131
[TBL] [Abstract][Full Text] [Related]
27. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
Kim YJ; Ahn H; Kim CS; Kim YS
Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
[TBL] [Abstract][Full Text] [Related]
28. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
29. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
Jabbari S; Weinberg VK; Shinohara K; Speight JL; Gottschalk AR; Hsu IC; Pickett B; McLaughlin PW; Sandler HM; Roach M
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):36-42. PubMed ID: 19409729
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced prostate cancer: preliminary results.
Fan CY; Chao HL; Huang WY; Lin CS; Chen CM; Lo CH
Tumori; 2015; 101(6):684-91. PubMed ID: 26045107
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.
King CR; Freeman D; Kaplan I; Fuller D; Bolzicco G; Collins S; Meier R; Wang J; Kupelian P; Steinberg M; Katz A
Radiother Oncol; 2013 Nov; 109(2):217-21. PubMed ID: 24060175
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
[TBL] [Abstract][Full Text] [Related]
34. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
[TBL] [Abstract][Full Text] [Related]
36. Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer.
Fukuokaya W; Kim S; Natsuyama T; Matsuzaki K; Shiomi H; Kitoh H; Utsumi N; Kurosaki H; Inoue M; Akakura K
Int J Clin Oncol; 2018 Apr; 23(2):361-367. PubMed ID: 29151227
[TBL] [Abstract][Full Text] [Related]
37. Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
Kataria S; Koneru H; Guleria S; Danner M; Ayoob M; Yung T; Lei S; Collins BT; Suy S; Lynch JH; Kole T; Collins SP
Front Oncol; 2017; 7():157. PubMed ID: 28791252
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.
Alayed Y; Loblaw A; Chu W; Al-Hanaqta M; Chiang A; Jain S; Chung H; Vesprini D; Morton G; Ravi A; Davidson M; Deabreu A; Mamedov A; Zhang L; Erler D; Cheung P
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1066-1073. PubMed ID: 31002941
[TBL] [Abstract][Full Text] [Related]
40. Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
Hu HP; Anagnostopoulos G; Gouran-Savadkoohi M; Dayes I; Ishkanian A; Hallock A; Lukka H; Quan K; Schnarr K; Cuthbert D; Goldberg M; Chang YM; Tsakiridis T
Prostate; 2024 Feb; 84(2):193-202. PubMed ID: 37880911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
